Primary tumor location and survival in colorectal cancer: A retrospective cohort study

Figure 1 Study profile. ¹Patients who received both 5-fluorouracil/leucovorin/oxaliplatin and 5-fluorouracil/leucovorin/irinotecan (i.e. 5-fluorouracil/leucovorin/ oxaliplatin/irinotecan) in the first-line were excluded. In addition, patients who received any other drugs as part of first-line therapy were excluded. ²Biomarker status for KRAS wild-type before or within 28 d of starting first-line therapy. If a patient had more than one successful test with a conflicting result during this window, the test result closest to the index date was used. In cases with conflicting test results on the same day, patients were excluded. CRC: Colorectal cancer; ICD: International Statistical Classification of Diseases and Related Health Problems; FOLFIRI: 5-fluorouracil/leucovorin/irinotecan; FOLFOX: 5-fluorouracil/ leucovorin/oxaliplatin; mCRC: Metastatic colorectal cancer; WT: Wild-type.